Artificial Intelligence-Driven Insights into the Antioxidant and Anticancer Properties of Onion (Allium cepa) and Tomato (Solanum lycopersicum) in Prostate Cancer Prevention and Management: A Contemporary Review

Technical Summary: AI-Driven Insights into the Antioxidant and Anticancer Properties of Onion and Tomato in Prostate Cancer

Problem Statement
Prostate cancer (PCa) remains a leading cause of cancer mortality in men, with current therapeutic limitations including castration-resistant prostate cancer (CRPC), multidrug resistance, and dose-limiting toxicities. A critical pathway in PCa pathogenesis is the oxidative stress-inflammatory axis, involving Reactive Oxygen Species (ROS)-induced DNA damage, NF-κB activation, and Androgen Receptor (AR) dysregulation. While dietary phytochemicals from Allium cepa (onion) and Solanum lycopersicum (tomato) show chemopreventive potential, their translation from bench to bedside is hindered by:

1. Limited systematic characterization of molecular targets and mechanisms.
2. Suboptimal bioavailability of active compounds (e.g., quercetin and lycopene).
3. Absence of predictive frameworks for prioritizing compounds, particularly given the polypharmacological nature of natural products.
4. Ambiguous clinical evidence, where meta-analyses often show no significant effect of lycopene supplementation on Prostate-Specific Antigen (PSA) levels.

Methodology
This study employs an integrative contemporary review methodology, synthesizing data from experimental phytochemistry, molecular oncology, and computational biology (2004–2025). The approach is structured around three interrelated pillars:

1. Oxidative Stress-Inflammation-Cancer Axis: Analyzing how phytochemicals modulate ROS, Nrf2/ARE pathways, and inflammatory markers.
2. Phytochemical Polypharmacology: Mapping multi-target interactions using network pharmacology and systems biology, moving beyond the "one drug, one target" paradigm.
3. AI-Enhanced Drug Discovery: Utilizing computational tools including molecular docking, molecular dynamics (MD) simulations, network pharmacology, machine learning (ML) for QSAR modeling, and deep learning for metabolite profiling.

The review aggregates evidence from in vitro (LNCaP, PC-3, DU145 cell lines), in vivo (xenograft, TRAMP models), and clinical trials, filtered through quality assessment tools (ToxRTool, SYRCLE, Cochrane RoB 2).

Key Contributions
The paper offers five primary contributions to the field:

1. Integrated Phytochemical-Antioxidant Mapping: It contrasts the complementary mechanisms of onion and tomato. Onion-derived quercetin activates the Nrf2/ARE pathway via electrophilic modification of Keap1 and direct radical scavenging. Tomato-derived lycopene quenches singlet oxygen via its conjugated polyene chain and inhibits lipid peroxidation. The review highlights that processed tomato products and onion peel extracts often possess superior bioavailability and potency compared to raw forms or isolated supplements.
2. Mechanistic Deconvolution of Polypharmacology: The review maps specific molecular targets, identifying quercetin as a preferential inhibitor of metastatic, androgen-independent PCa (via PI3K/Akt and Wnt/β-catenin disruption) and lycopene as a suppressor of androgen-driven proliferation (via 5α-reductase inhibition and AR translocation blockade). It validates the "tomato effect," suggesting whole-food matrices offer synergistic benefits over isolated lycopene.
3. AI-Methodology Synthesis: It unifies scattered AI applications into a translational pipeline, validating tools such as AutoDock Vina, AlphaFold2-assisted docking, and random forest algorithms for predicting antioxidant capacity from metabolomic profiles (R² > 0.85).
4. Gap-Directed Research Agenda: The review identifies critical gaps: the need for bioavailability optimization (nanoformulation), the necessity of moving beyond PSA as a sole biomarker, and the requirement for AI models retrained on natural product datasets to reduce synthetic compound bias.
5. Methodological Innovation: It proposes a blueprint for future interdisciplinary reviews that prioritize conceptual synthesis and mechanistic deconvolution over simple evidence aggregation.

Results

• Molecular Docking & AI: AI-driven molecular docking identified quercetin as a high-affinity binder to the Androgen Receptor (binding energy −9.2 kcal/mol), surpassing the reference drug enzalutamide (−8.4 kcal/mol). Network pharmacology identified quercetin, kaempferol, and isorhamnetin as hub compounds enriching prostate cancer, PI3K-Akt, and apoptosis pathways.
• Experimental Evidence: In vitro studies showed onion-derived nanovesicles (ODNVs) induced S-phase arrest and apoptosis in PC-3 cells. Lycopene was shown to induce G0/G1 and G2/M cell cycle arrest and upregulate p21/p27.
• Clinical Evidence: Clinical trials and meta-analyses remain equivocal. A meta-analysis of 6 RCTs (n=354) found no significant effect of lycopene supplementation on PSA levels. However, exploratory analyses suggest potential benefits in specific subpopulations (e.g., those not receiving chemotherapy or with high baseline PSA) and reduced tumor proliferation in pre-surgical windows.
• Bioavailability: Thermal processing of tomatoes increases lycopene bioavailability 2–3 fold. Conversely, quercetin faces extensive Phase II metabolism (glucuronidation/sulfation), limiting systemic activity.

Significance
The paper claims significance as one of the first comprehensive syntheses linking experimental phytochemistry, molecular oncology, and AI-driven drug discovery specifically for Allium cepa and Solanum lycopersicum in the context of prostate cancer.

• For Researchers: It provides a validated framework for using AI to prioritize natural products, suggesting a shift from single-target screening to network-based approaches.
• For Public Health: It offers evidence for dietary intervention strategies, particularly for resource-limited settings, advocating for functional foods (processed tomatoes, onion peels) as accessible chemopreventive agents.
• For Industry: It outlines a pathway for developing precision nutraceuticals and adjuvant therapies, emphasizing the need for nanoformulation and multi-omic biomarker refinement to overcome current translational barriers.

The review concludes that while the antioxidant and anticancer properties of these bioactives are well-supported experimentally, their clinical utility depends on optimizing bioavailability, refining biomarkers, and leveraging AI to formulate synergistic, patient-specific interventions.